Skip to main content

Table 5 Clinical features analysed for the patients receiving carbapenem or other AIT between day > 0 and day 30

From: Epidemiology and prognosis of anti-infective therapy in the ICU setting during acute pancreatitis: a cohort study

 Missing dataCarbapenems n = 202Other AIT n = 364p value
Severity criteria on admission
 SOFA score, median [IQR]4/85 [3–7]5 [3–6]NS
 Respiratory failure*, n (%)074 (37)123 (34)NS
 Cardiovascular failure*, n (%)079 (39)118 (32)NS
 Renal failure*, n (%)039 (19)77 (21)NS
 Septic shock, n (%)045 (22)65 (18)NS
 Acute respiratory distress syndrome, n (%)027 (13)25 (7)< 0.05
Main treatments between day > 0 and day 30
 Need for red blood cell transfusion, n (%)087 (43)104 (29)< 0.001
 Number of days of mechanical ventilation5/512 [2–26]2 [0–10]< 0.001
 Vasoactive support, n (%)0/1147 (73)184 (51)< 0.001
 Renal replacement therapy, n (%)0/182 (41)94 (26)< 0.001
 Duration of RRT, days, median [IQR]6/510 [3–22]5 [2–13]< 0.01
Main complications between day > 0 and day 30
 Acute respiratory distress syndrome, n (%)1/1101 (50)100 (28)< 0.001
 Septic shock, n (%)15/31102 (55)106 (32)< 0.001
 Pancreatic necrosis, n (%)4/14156 (79)229 (65)< 0.001
 Infected necrosis, n (%)8/2096 (49)100 (29)< 0.001
 Gastro-intestinal perforation, n (%)12/1823 (12)27 (8)NS
 Vascular thrombosis, n (%)9/1636 (19)47 (14)NS
 Acute mesenteric ischaemia, n (%)10/1726 (14)36 (10)NS
 Intra-abdominal collection, n (%)6/15105 (54)131 (38)< 0.001
 Abdominal compartment syndrome, n (%)9/1733 (17)32 (9)< 0.01
 Haemorrhage, n (%)8/1844 (23)35 (10)< 0.001
 Peritonitis, n (%)11/1936 (19)47 (14)NS
 Cholangitis, n (%)8/1718 (9)39 (11)NS
 Digestive fistula, n (%)10/1811 (6)19 (5)NS
Clinical management between day > 0 and day 30
 Endoscopic necrosectomy, n (%)1/576 (38)71 (20)< 0.001
 Surgical necrosectomy, n (%)1/594 (47)123 (34)< 0.01
 Radiological drainage, n (%)1/563 (31)56 (16)< 0.001
 Main reasons for anti-infective therapy between day > 0 and day 30
 Intra-abdominal infection, n (%)11/13153 (80)194 (55)< 0.001
 Pneumonia, n (%)11/1479 (41)89 (25)< 0.001
 Bacteraemia, n (%)10/1560 (31)76 (22)< 0.05
Anti-infective therapy administered between day > 0 and day 30
 Duration of AIT, days, median [IQR]8/1610 [3–17]5 [2–10]< 0.001
 Aminoglycosides, n (%)4/19129 (65)118 (34)< 0.001
 Anti-Gram-positive agents, n (%)10/23101 (53)60 (18)< 0.001
 Antifungal agents, n (%)0/254 (27)56 (15)< 0.01
 Azoles, n (%)6/232 (16)35 (10)< 0.05
 Echinocandins, n (%)6/224 (12)20 (6)< 0.01
Duration of ICU stay, days, median [IQR]022 [9–39]8 [3–19]< 0.001
ICU readmission n (%)1/021 (10)29 (8)NS
Hospital mortality rate, n (%)064 (32)77 (21)< 0.01
Time to death, days, median [IQR]029 [11–45]4 [1–18]< 0.001
  1. NS non-significant, NA not applicable, ERCP endoscopic retrograde cholangiopancreatography
  2. *According to the definition of the SOFA score